- Home
- PMCB vs SILO Comparison
PMCB vs SILO Comparison
Compare PMCB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- SILO
- Stock Information
- Founded
- PMCB 1996
- SILO 2010
- Country
- PMCB United States
- SILO United States
- Employees
- PMCB N/A
- SILO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- SILO Apparel
- Sector
- PMCB Health Care
- SILO Consumer Discretionary
- Exchange
- PMCB Nasdaq
- SILO Nasdaq
- Market Cap
- PMCB 6.6M
- SILO 5.9M
- IPO Year
- PMCB N/A
- SILO N/A
- Fundamental
- Price
- PMCB $0.94
- SILO $0.61
- Analyst Decision
- PMCB
- SILO
- Analyst Count
- PMCB 0
- SILO 0
- Target Price
- PMCB N/A
- SILO N/A
- AVG Volume (30 Days)
- PMCB 118.7K
- SILO 307.3K
- Earning Date
- PMCB 09-12-2025
- SILO 08-13-2025
- Dividend Yield
- PMCB N/A
- SILO N/A
- EPS Growth
- PMCB N/A
- SILO N/A
- EPS
- PMCB 3.19
- SILO N/A
- Revenue
- PMCB N/A
- SILO $72,102.00
- Revenue This Year
- PMCB N/A
- SILO $1.86
- Revenue Next Year
- PMCB N/A
- SILO N/A
- P/E Ratio
- PMCB $0.30
- SILO N/A
- Revenue Growth
- PMCB N/A
- SILO N/A
- 52 Week Low
- PMCB $0.80
- SILO $0.41
- 52 Week High
- PMCB $2.42
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- PMCB 47.20
- SILO 44.10
- Support Level
- PMCB $0.92
- SILO $0.59
- Resistance Level
- PMCB $1.00
- SILO $0.67
- Average True Range (ATR)
- PMCB 0.09
- SILO 0.04
- MACD
- PMCB 0.00
- SILO -0.01
- Stochastic Oscillator
- PMCB 28.69
- SILO 14.33
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.